利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

49 条记录 (耗时 0.021 秒)

    Composition comprising a cell expressing an AC133 cell surface antigen and an antibody or antigen-binding fragment
    1.
    发明授权
    Composition comprising a cell expressing an AC133 cell surface antigen and an antibody or antigen-binding fragment 失效
    包含表达AC133细胞表面抗原的细胞和抗体或抗原结合片段的组合物

    公开(公告)号：US08084033B2

    公开(公告)日：2011-12-27

    申请号：US12169336

    申请日：2008-07-08

    申请人： Amy H. Yin ,  Sheri Miraglia ,  Wayne G. Godfrey ,  David W. Buck

    发明人： Amy H. Yin ,  Sheri Miraglia ,  Wayne G. Godfrey ,  David W. Buck

    IPC分类号： A61K39/00 ,  A61K39/395 ,  C07K16/00 ,  C07K17/00 ,  C12P21/08

    CPC分类号： C07K14/705 ,  C07K16/28 ,  G01N33/56966 ,  Y10S530/806 ,  Y10S530/838

    摘要： Compositions comprising a cell expressing an AC133 cell surface antigen and an antibody, or antigen binding fragment thereof, that specifically binds to the antigen are provided. Expression of the antigen is highly tissue specific. It is detected on a subset of hematopoietic progenitor and stem cells derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood. The subset of cells recognized by AC133 is CD34bright and contains substantially all of the CFU-GM activity present in the CD34+ population. This highly specific distribution of AC133 makes it exceptionally useful as a reagent for isolating and characterizing human hematopoietic progenitor and stem cells. Cells selected for expression of AC133 antigen can be further purified by selection for other hematopoietic stem cell and progenitor cell markers.

    摘要翻译： 提供了包含特异性结合抗原的表达AC133细胞表面抗原的细胞和抗体或其抗原结合片段的组合物。 抗原的表达是高度组织特异性的。 在源自人骨髓，胎儿骨髓和肝脏，脐带血和成人外周血的造血祖细胞和干细胞的子集上检测到。 由AC133识别的细胞亚群是CD34bright并且基本上包含存在于CD34 +群体中的所有CFU-GM活性。 这种高度特异性的AC133分布使其特别有用作分离和表征人类造血祖细胞和干细胞的试剂。 选择用于表达AC133抗原的细胞可以通过选择其他造血干细胞和祖细胞标记进一步纯化。

    Human Hematopoietic Stem And Progenitor Antigen And Methods For Its Use
    2.
    发明申请
    Human Hematopoietic Stem And Progenitor Antigen And Methods For Its Use 失效
    人造血干细胞和祖细胞抗原及其使用方法

    公开(公告)号：US20090093052A1

    公开(公告)日：2009-04-09

    申请号：US12169336

    申请日：2008-07-08

    申请人： Amy H. Yin ,  Sheri Miraglia ,  David W. Buck

    发明人： Amy H. Yin ,  Sheri Miraglia ,  David W. Buck

    IPC分类号： C12N5/06 ,  C12N5/00

    CPC分类号： C07K14/705 ,  C07K16/28 ,  G01N33/56966 ,  Y10S530/806 ,  Y10S530/838

    摘要： A hematopoietic progenitor cell antigen and reagents, notably antibodies, that specifically bind to the antigen are provided. Expression of the antigen is highly tissue specific. It is only detected on a subset of hematopoietic progenitor cells derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood. The subset of cells recognized by AC133 is CD34bright and contains substantially all of the CFU-GM activity present in the CD34+ population. This highly specific distribution of AC133 makes it exceptionally useful as a reagent for isolating and characterizing human hematopoietic progenitor and stem cells. Cells selected for expression of AC133 antigen can be further purified by selection for other hematopoietic stem cell and progenitor cell markers.

    摘要翻译： 提供了特异性结合抗原的造血祖细胞抗原和试剂，特别是抗体。 抗原的表达是高度组织特异性的。 仅在衍生自人骨髓，胎儿骨髓和肝脏，脐带血和成人外周血的造血祖细胞的子集上检测到。 由AC133识别的细胞亚群是CD34bright并且基本上包含存在于CD34 +群体中的所有CFU-GM活性。 这种高度特异性的AC133分布使其特别有用作分离和表征人类造血祖细胞和干细胞的试剂。 选择用于表达AC133抗原的细胞可以通过选择其他造血干细胞和祖细胞标记进一步纯化。

    Myeloid cell leukemia associated gene MCL-1
    3.
    发明授权
    Myeloid cell leukemia associated gene MCL-1 失效
    骨髓细胞白血病相关基因MCL-1

    公开(公告)号：US06528263B1

    公开(公告)日：2003-03-04

    申请号：US09687260

    申请日：2000-10-12

    申请人： Ruth W. Craig

    发明人： Ruth W. Craig

    IPC分类号： C12Q168

    CPC分类号： C07K14/4747 ,  A61K38/00 ,  Y10S530/828 ,  Y10S530/838

    摘要： A gene, mc1-1, of the bc1-2 family is disclosed along with its nucleotide and amino acid sequence. Also disclosed are diagnostic and therapeutic methods of utilizing the mc1-1 nucleotide and polypeptide sequences.

    摘要翻译： 公开了bc1-2家族的基因mc1-1及其核苷酸和氨基酸序列。 还公开了利用mc1-1核苷酸和多肽序列的诊断和治疗方法。

    Antiviral agent comprising CD4 and H2 histone
    5.
    发明授权
    Antiviral agent comprising CD4 and H2 histone 失效
    包含CD4和H2组蛋白的抗病毒剂

    公开(公告)号：US5714462A

    公开(公告)日：1998-02-03

    申请号：US335740

    申请日：1994-12-30

    申请人： Donald Selwyn Davies ,  Sunil Shaunak ,  Nigel John Gooderham ,  Robert John Edwards

    发明人： Donald Selwyn Davies ,  Sunil Shaunak ,  Nigel John Gooderham ,  Robert John Edwards

    IPC分类号： A61K38/00 ,  A61K38/17 ,  A61P31/12 ,  A61K38/16 ,  A61K39/21 ,  C07K1/00

    CPC分类号： A61K38/1709 ,  A61K38/1774 ,  Y10S530/837 ,  Y10S530/838

    摘要： The invention provides an agent against HIV and/or related viruses, comprising CD4 or a CD4-like substance and an H2 histone or an H2 histone-like protein. The content of the CD4 or CD4-like substance is preferably less than the antivirally effective dose of that substance alone. The invention also provides an H2 histone or an H2-like protein, for use in a method of medical treatment, in particular against HIV and/or related viruses, and also for use in the manufacture of a pharmaceutical composition against HIV and/or related viruses.

    摘要翻译： PCT No.PCT / GB93 / 00934 Sec。 371日期1994年12月30日第 102（e）日期1994年12月30日PCT提交1993年5月6日PCT公布。 公开号WO93 / 21943 日期1993年11月11日本发明提供了抗HIV和/或相关病毒的试剂，其包含CD4或CD4样物质和H2组蛋白或H2组蛋白样蛋白。 CD4或CD4样物质的含量优选小于该物质单独的抗病毒有效剂量。 本发明还提供用于治疗方法，特别是针对HIV和/或相关病毒的H2组蛋白或H2样蛋白，并且还用于制造抗HIV和/或相关的药物组合物 病毒

    Treatment of symptoms of neoplastic diseases with nucleoproteins
    6.
    发明授权
    Treatment of symptoms of neoplastic diseases with nucleoproteins 失效
    用核蛋白治疗肿瘤性疾病症状

    公开(公告)号：US4701442A

    公开(公告)日：1987-10-20

    申请号：US744341

    申请日：1985-06-13

    申请人： Emanuel Revici

    发明人： Emanuel Revici

    IPC分类号： A61K38/00 ,  C07K14/47 ,  C07K15/18

    CPC分类号： C07K14/47 ,  A61K38/00 ,  Y10S530/82 ,  Y10S530/821 ,  Y10S530/823 ,  Y10S530/825 ,  Y10S530/837 ,  Y10S530/838 ,  Y10S530/844 ,  Y10S530/846 ,  Y10S530/852

    摘要： A process for preparing nucleoproteic material which comprises immersing organic material into a suitable solvent for a sufficient time to extract nucleoproteins from said material, adding a sufficient amount of an acid to form a precipitate of nucleoproteic material, and recovering said nucleoproteic material precipitate. A composition of nucleoproteic material produced according to this process. A method for alleviating symptoms of neoplastic diseases which comprises sterilizing the composition of nucleoproteic material, preparing a formulation comprising an effective amount of said sterilized composition, and administering said formulation to a patient having symptoms of a neoplastic disease.

    摘要翻译： 一种制备核蛋白材料的方法，其包括将有机材料浸入合适的溶剂中足够的时间以从所述材料中提取核蛋白，加入足够量的酸形成核蛋白材料的沉淀物，并回收所述核蛋白材料沉淀物。 根据该方法生产的核蛋白材料的组合物。 一种用于减轻肿瘤疾病症状的方法，其包括对所述核蛋白材料的组合物进行消毒，制备包含有效量的所述灭菌组合物的制剂，以及将所述制剂施用于具有肿瘤性疾病症状的患者。

    Human hematopoietic stem and progenitor antigen and methods for its use
    7.
    发明申请
    Human hematopoietic stem and progenitor antigen and methods for its use 审中-公开
    人类造血干细胞和祖细胞抗原及其使用方法

    公开(公告)号：US20050214861A1

    公开(公告)日：2005-09-29

    申请号：US10827907

    申请日：2004-04-19

    申请人： Amy Yin ,  Sheri Miraglia ,  David Buck

    发明人： Amy Yin ,  Sheri Miraglia ,  David Buck

    IPC分类号： C12N15/02 ,  C07K14/47 ,  C07K14/705 ,  C07K16/18 ,  C07K16/28 ,  C07K16/40 ,  C12N5/06 ,  C12N5/08 ,  C12N5/10 ,  C12N5/20 ,  C12N15/12 ,  C12P21/08 ,  G01N33/53 ,  G01N33/569 ,  G01N33/577

    CPC分类号： C07K14/705 ,  C07K16/28 ,  G01N33/56966 ,  Y10S530/806 ,  Y10S530/838

    摘要： A hematopoietic progenitor cell antigen and reagents, notably antibodies, that specifically bind to the antigen are provided. Expression of the antigen is highly tissue specific. It is only detected on a subset of hematopoietic progenitor cells derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood. The subset of cells recognized by AC133 is CD34bright and contains substantially all of the CFU-GM activity present in the CD34+ population. This highly specific distribution of AC133 makes it exceptionally useful as a reagent for isolating and characterizing human hematopoietic progenitor and stem cells. Cells selected for expression of AC133 antigen can be further purified by selection for other hematopoietic stem cell and progenitor cell markers.

    摘要翻译： 提供了特异性结合抗原的造血祖细胞抗原和试剂，特别是抗体。 抗原的表达是高度组织特异性的。 仅在衍生自人骨髓，胎儿骨髓和肝脏，脐带血和成人外周血的造血祖细胞的子集上检测到。 由AC133识别的细胞亚群是CD34 亮，并且基本上包含存在于CD34 + +群体中的基本上所有的CFU-GM活性。 这种高度特异性的AC133分布使其特别有用作分离和表征人类造血祖细胞和干细胞的试剂。 选择用于表达AC133抗原的细胞可以通过选择其他造血干细胞和祖细胞标记进一步纯化。

    Human hematopoietic stem and progenitor cell antigen
    8.
    发明授权
    Human hematopoietic stem and progenitor cell antigen 失效
    人造血干细胞和祖细胞抗原

    公开(公告)号：US06455678B1

    公开(公告)日：2002-09-24

    申请号：US08842382

    申请日：1997-04-23

    申请人： Amy H. Yin ,  Sheri Miraglia ,  Wayne G. Godfry ,  David W. Buck

    发明人： Amy H. Yin ,  Sheri Miraglia ,  Wayne G. Godfry ,  David W. Buck

    IPC分类号： C07K100

    CPC分类号： C07K14/705 ,  C07K16/28 ,  G01N33/56966 ,  Y10S530/806 ,  Y10S530/838

    摘要： A hematopoietic progenitor cell antigen and reagents, notably antibodies, that specifically bind to the antigen are provided. Expression of the antigen is highly tissue specific. It is only detected on a subset of hematopoietic progenitor cells derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood. The subset of cells recognized by AC133 is CD34bright and contains substantially all of the CFU-GM activity present in the CD34+ population. This highly specific distribution of AC133 makes it exceptionally useful as a reagent for isolating and characterizing human hematopoietic progenitor and stem cells. Cells selected for expression of AC133 antigen can be further purified by selection for other hematopoietic stem cell and progenitor cell markers.

    摘要翻译： 提供了特异性结合抗原的造血祖细胞抗原和试剂，特别是抗体。 抗原的表达是高度组织特异性的。 仅在衍生自人骨髓，胎儿骨髓和肝脏，脐带血和成人外周血的造血祖细胞的子集上检测到。 由AC133识别的细胞亚群是CD34bright并且基本上包含存在于CD34 +群体中的所有CFU-GM活性。 这种高度特异性的AC133分布使其特别有用作分离和表征人类造血祖细胞和干细胞的试剂。 选择用于表达AC133抗原的细胞可以通过选择其他造血干细胞和祖细胞标记进一步纯化。